In conclusion, in this placebo-controlled, randomized trial, the potent and selective PPARδ agonist seladelpar, at an optimal dose of 10 mg daily, provided clinically significant anticholestatic effects and reduced signs of liver injury and pruritus in patients with PBC. Here, PPARD is linked to primary biliary cholangitis.